1. Generics Bulletin
  2. >>Products

MPP Strikes Deal For Long-Acting Injectable HIV Candidate

Monthly Subcutaneous Injection Licensed From University Of Washington Could Replace Daily Pills

 
• By Chloe Kent

The University of Washington has agreed to license an in-development HIV treatment to the Medicines Patent Pool, which takes the form of a monthly subcutaneous injection instead of daily oral treatment.

HIV ribbon
MPP has added another HIV candidate to its portfolio • Source: Alamy

The Medicines Patent Pool has signed a license agreement with the University of Washington for a long-acting injectable drug combination candidate being developed for use as an HIV treatment. The project is being supported by MPP’s founder Unitaid through its Global Long-Acting Drug project.

The license incorporates the “patents and expertise” relating to the candidate, which aims to transform the World Health Organization recommended daily oral dosage of TLD (tenofovir/lamivudine/dolutegravir) into a monthly subcutaneous injection

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.